DE60214355D1 - Exemestan zur behandlung von hormonabhängigen störungen - Google Patents

Exemestan zur behandlung von hormonabhängigen störungen

Info

Publication number
DE60214355D1
DE60214355D1 DE60214355T DE60214355T DE60214355D1 DE 60214355 D1 DE60214355 D1 DE 60214355D1 DE 60214355 T DE60214355 T DE 60214355T DE 60214355 T DE60214355 T DE 60214355T DE 60214355 D1 DE60214355 D1 DE 60214355D1
Authority
DE
Germany
Prior art keywords
exemestan
hormone
treatment
related disorder
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60214355T
Other languages
English (en)
Other versions
DE60214355T2 (de
Inventor
Salle Enrico Di
Gabriella Piscitelli
Giorgio Massimini
Dinesh Purandare
Hendrik Dekoning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Pharmacia and Upjohn Co LLC
Original Assignee
Pfizer Italia SRL
Pharmacia and Upjohn Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Italia SRL, Pharmacia and Upjohn Co LLC filed Critical Pfizer Italia SRL
Publication of DE60214355D1 publication Critical patent/DE60214355D1/de
Application granted granted Critical
Publication of DE60214355T2 publication Critical patent/DE60214355T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DE60214355T 2001-01-26 2002-01-18 Exemestan zur behandlung von hormonabhängigen störungen Expired - Fee Related DE60214355T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US770911 1985-08-30
US77091101A 2001-01-26 2001-01-26
PCT/EP2002/000638 WO2002072106A2 (en) 2001-01-26 2002-01-18 Combined method for treating hormono-dependent disorders with exemestane

Publications (2)

Publication Number Publication Date
DE60214355D1 true DE60214355D1 (de) 2006-10-12
DE60214355T2 DE60214355T2 (de) 2007-08-30

Family

ID=25090093

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60214355T Expired - Fee Related DE60214355T2 (de) 2001-01-26 2002-01-18 Exemestan zur behandlung von hormonabhängigen störungen

Country Status (12)

Country Link
EP (1) EP1377298B1 (de)
JP (1) JP2004519490A (de)
AR (1) AR032268A1 (de)
AT (1) ATE337787T1 (de)
CA (1) CA2434611A1 (de)
DE (1) DE60214355T2 (de)
DK (1) DK1377298T3 (de)
ES (1) ES2269682T3 (de)
MX (1) MXPA03006607A (de)
PE (1) PE20020843A1 (de)
PT (1) PT1377298E (de)
WO (1) WO2002072106A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
WO2003017974A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
US20060173062A1 (en) * 2003-06-20 2006-08-03 Boice Judith A Use of selective cyclooxygenase-2 inhibitors for the treatment of endometriosis
EP1951242A2 (de) 2005-11-22 2008-08-06 Incyte Corporation Kombinationstherapie zur behandlung von krebs
AU2007230716B2 (en) 2006-03-28 2012-05-03 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
WO2008019048A1 (en) * 2006-08-04 2008-02-14 Meditrina Pharmaceuticals Use of aromatase inhibitors for thining the endometrium or treating menorrhagia
CN101717393A (zh) * 2009-12-01 2010-06-02 陈依军 环己基2,5-二取代苯基醚的衍生物及其应用
DE102010003494A1 (de) * 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
EP3205648A1 (de) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Östrogenrezeptormodulatoren und verwendungen davon
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
JP6215335B2 (ja) 2013-09-24 2017-10-18 富士フイルム株式会社 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体
SG11201805387RA (en) 2015-12-30 2018-07-30 Univ Saint Louis Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
CN113712974A (zh) * 2021-08-20 2021-11-30 南京大学 阿司匹林在制备治疗子宫内膜增生药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
GB8617107D0 (en) * 1986-07-14 1986-08-20 Erba Farmitalia 6-/7-methylenandrosta-1 4-diene-3 17-dione derivatives
NZ261123A (en) * 1993-02-18 1996-08-27 Erba Carlo Spa Fluorinated 4-aminoandrostadienone derivatives
GB9313420D0 (en) * 1993-06-29 1993-08-11 Erba Carlo Spa Fluorinated 6-methylenandrosta-1,4-dien-3-one-derivatives and process for their preparations
BR9916536A (pt) * 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
CA2409652A1 (en) * 2000-05-15 2001-11-22 Giorgio Massimini Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents
AU2001289865B2 (en) * 2000-09-08 2007-03-01 Pharmacia Italia S.P.A. Exemestane as chemopreventing agent

Also Published As

Publication number Publication date
EP1377298B1 (de) 2006-08-30
WO2002072106A3 (en) 2003-10-30
AR032268A1 (es) 2003-10-29
PE20020843A1 (es) 2002-09-25
DK1377298T3 (da) 2007-01-02
ATE337787T1 (de) 2006-09-15
MXPA03006607A (es) 2003-09-22
CA2434611A1 (en) 2002-09-19
PT1377298E (pt) 2006-12-29
WO2002072106A2 (en) 2002-09-19
ES2269682T3 (es) 2007-04-01
JP2004519490A (ja) 2004-07-02
EP1377298A2 (de) 2004-01-07
DE60214355T2 (de) 2007-08-30

Similar Documents

Publication Publication Date Title
DE60234760D1 (de) Phenylindole zur behandlung von hiv
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE60113496D1 (de) Verwendung von Glycyrrhizin zur Behandlung von Mastitis.
ATE556059T1 (de) Pyrazolderivate zur behandlung von hiv
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60103137D1 (de) Impstoff zur behandlung von atherosclerosis
DE60233718D1 (de) Wasserbasierendes hydrophobiermittel zur behandlung von substraten
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE69925865D1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60229959D1 (de) Kombinationstherapie zur behandlung von krebs
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE60030554D1 (de) Verwendungen von et743 zur behandlung von krebs
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE60214355D1 (de) Exemestan zur behandlung von hormonabhängigen störungen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE60223718D1 (de) Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen
DE60308045D1 (de) Pflanzenextrakte aus argyrolobium roseum zur behandlung von diabetes
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee